Avantor EVP Biopharma Production Gerard Brophy to retire, step down Oct 2, 2023

Avantor, Inc.

Gerard Brophy will step down as EVP Biopharma Production on October 2, 2023.
He will retire from the company effective February 29, 2024.
After retirement, Brophy will remain Chair of the Scientific Advisory Board and advisor to the company.
Brophy was a named executive officer in Avantor's 2023 proxy statement.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Gerard Brophy

Executive Vice President, Biopharma Production

AVTR · Avantor, Inc.

Effective: 2023-10-02
Filed: September 26, 2023, 7:59 PM ET

On September 26, 2023, Avantor, Inc. (the “Company”) announced that Dr. Gerard Brophy, the Company’s Executive Vice President, Biopharma Production and a named executive officer in the Company’s definitive proxy statement on Schedule 14A filed on March 31, 2023, will be stepping down from that position on October 2, 2023, and retiring from the Company effective February 29, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gerard Brophy departed as Executive Vice President, Biopharma Production at Avantor, Inc..

Action: stepping down
Role: Executive Vice President, Biopharma Production

Exact text from the filing

On September 26, 2023, Avantor, Inc. (the “Company”) announced that Dr. Gerard Brophy, the Company’s Executive Vice President, Biopharma Production and a named executive officer in the Company’s definitive proxy statement on Schedule 14A filed on March 31, 2023, will be stepping down from that position on October 2, 2023, and retiring from the Company effective February 29, 2024.

View on SEC.gov

Avantor, Inc. filing history →

Source: SEC EDGAR

accession 0001722482-23-000179

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.